Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
Public ClinicalTrials.gov record NCT02274766. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)
Study identification
- NCT ID
- NCT02274766
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Adamas Pharmaceuticals, Inc.
- Industry
- Enrollment
- 77 participants
Conditions and interventions
Interventions
- ADS-5102 Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 30 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2014
- Primary completion
- Mar 9, 2016
- Completion
- Mar 9, 2016
- Last update posted
- Jan 9, 2018
2014 – 2016
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Fountain Valley | California | 92708 | — |
| Not listed | Sunnyvale | California | 94085 | — |
| Not listed | Boca Raton | Florida | 33486 | — |
| Not listed | Jacksonville | Florida | 32209 | — |
| Not listed | Port Charlotte | Florida | 33980 | — |
| Not listed | Sunrise | Florida | 33351 | — |
| Not listed | Tampa | Florida | 33612 | — |
| Not listed | Atlanta | Georgia | 30329 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Kansas City | Kansas | 66160 | — |
| Not listed | Baltimore | Maryland | 21287 | — |
| Not listed | Elkridge | Maryland | 21075 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | West Bloomfield | Michigan | 48322 | — |
| Not listed | Greensboro | North Carolina | 27405 | — |
| Not listed | Raleigh | North Carolina | 27607 | — |
| Not listed | Tulsa | Oklahoma | 74136 | — |
| Not listed | Roanoke | Virginia | 24018 | — |
| Not listed | Kirkland | Washington | 98034 | — |
| Not listed | Morgantown | West Virginia | 26506 | — |
| Not listed | Milwaukee | Wisconsin | 53233 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02274766, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 9, 2018 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02274766 live on ClinicalTrials.gov.